Clinical Trial Update: A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial update evaluating GFH375 in combination with cetuximab or chemotherapy for KRAS G12D-mutant solid tumors, including pancreati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Chemotherapy (unspecified)
• GFH375 (GFH375)

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: Advanced Solid Tumors Cancer, PDAC | Phase 1, Phase 2 | Status: RECRUITING